|
1
|
Ettinger DS, Akerley W, Bepler G, Blum MG,
Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, et
al: Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hsu WH, Yang JC, Mok TS and Loong HH:
Overview of current systemic management of EGFR-mutant NSCLC. Ann
Oncol. 29 (Suppl_1):i3–i9. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herbst RS, Baas P, Kim DW, Felip E,
Perez-Gracia JL and Han JY: Pembrolizumab versus docetaxel for
previously treated, PD-L1-positive, advanced non-small-cell lung
cancer (KEYNOTE-010): A randomized controlled trial. Lancet.
387:1540–1550. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T and Kowalski DM:
Atezolizumab versus docetaxel in patients with previously treated
non-small-cell lung cancer (OAK): A phase 3, open-label,
multicenter randomized controlled trial. Lancet. 389:255–265. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kowanetz M, Zou W, Gettinger SN, Koeppen
H, Kockx M, Schmid P, Kadel EE, Wistuba I, Chaft J, Rizvi NA, et
al: Differential regulation of PD-L1 expression by immune and tumor
cells in NSCLC and the response to treatment with atezolizumab
(anti-PD-L1). Proc Natl Acad Sci USA. 115:E10119–E10126. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim MY, Koh J, Kim S, Go H, Jeon YK and
Chung DH: Clinicopathological analysis of PD-L1 and PD-L2
expression in pulmonary squamous cell carcinoma: Comparison with
tumor-infiltrating T cells and the status of oncogenic drivers.
Lung Cancer. 88:24–33. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sumitomo R, Hirai T, Fujita M, Murakami H,
Otake Y and Huang C: PD-L1 expression on tumor-infiltrating immune
cells is highly associated with M2 TAM and aggressive malignant
potential in patients with resected non-small cell lung cancer.
Lung Cancer. 136:136–144. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shinchi Y, Komohara Y, Yonemitsu K, Sato
K, Ohnishi K, Saito Y, Fujiwara Y, Mori T, Shiraishi K, Ikeda K and
Suzuki M: Accurate expression of PD-L1/L2 in lung adenocarcinoma
cells: A retrospective study by double immunohistochemistry. Cancer
Sci. 110:2711–2721. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Matsubara T, Takada K, Azuma K, Takamori
S, Toyokawa G, Haro A, Osoegawa A, Tagawa T, Kawahara A, Akiba J,
et al: A clinicopathological and prognostic analysis of PD-L2
expression in surgically resected primary lung squamous cell
carcinoma. Ann Surg Oncol. 26:1925–1933. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Takamori S, Takada K, Azuma K, Jogo T,
Shimokawa M, Toyokawa G, Hirai F, Tagawa T, Kawahara A, Akiba J, et
al: Prognostic impact of programmed death-ligand 2 expression in
primary lung adenocarcinoma patients. Ann Surg Oncol. 26:1916–1924.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Baptista MZ, Sarian LO, Derchain SFM,
Pinto GA and Vassallo J: Prognostic significance of PD-L1 and PD-L2
in breast cancer. Hum Pathol. 47:78–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao SG, Lehrer J, Chang SL, Das R, Erho
N, Liu Y, Sjostrom M, Den RB, Freedland SJ, Klein EA, et al: The
immune landscape of prostate cancer and nomination of PD-L2 as a
potential therapeutic target. J Natl Cancer Inst. 111:301–310.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Okadome K, Baba Y, Nomoto D, Yagi T,
Kalikawe R, Harada K, Hiyoshi Y, Nagai Y, Ishimoto T, Iwatsuki M,
et al: Prognostic and clinical impact of PD-L2 and PD-L1 expression
in a cohort of 437 oesophageal cancers. Br J Cancer. 122:1535–1543.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Okazaki T and Honjo T: PD-1 and PD-1
ligands: From discovery to clinical application. Int Immunol.
19:813–824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rozali EN, Hato SV, Robinson BW, Lake RA
and Lesterhuis WJ: Programmed death ligand 2 in cancer-induced
immune suppression. Clin Dev Immunol. 2021:6563402012.PubMed/NCBI
|
|
17
|
Zhong X, Tumang JR, Gao W, Bai C and
Rothstein TL: PD-L2 expression extends beyond dendritic
cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and
phosphatidylcholine binding. Eur J Immunol. 37:2405–2410. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tanegashima T, Togashi Y, Azuma K,
Kawahara A, Ikeguchi K, Sugiyama D, Kinoshita F, Akiba J, Kashiwagi
E, Takeuchi A, et al: Immune suppression by PD-L2 against
spontaneous and treatment-related antitumor immunity. Clin Cancer
Res. 25:4808–4819. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Umezu D, Okada N, Sakoda Y, Adachi K,
Ojima T, Yamaue H, Eto M and Tamada K: Inhibitory functions of
PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine
tumor microenvironment. Cancer Immunol Immunother. 68:201–211.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yearley JH, Gibson C, Yu N, Moon C, Murphy
E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, et al: PD-L2
Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in
Cancer. Clin Cancer Res. 23:3158–3167. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amin MB, Edge S and Greene F: AJCC Cancer
Staging Manual. 8th edition. Springer; New York: 2017, View Article : Google Scholar
|
|
22
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: WHO Classification of Tumours of the Lung,
Pleura, Thymus and Heart. 4th edition. International Agency for
Research on Cancer; Lyon, France: 2015
|
|
23
|
Sumitomo R, Hirai T, Fujita M, Murakami H,
Otake Y and Huang C: M2 tumor-associated macrophages promote tumor
progression in non-small-cell lung cancer. Exp Ther Med.
18:4490–4498. 2019.PubMed/NCBI
|
|
24
|
Tsao MS, Kerr KM, Kockx M, Beasley M,
Borczuk AC, Botling J, Budendorf L, Chirieac L, Chen G, Chou T, et
al: PD-L1 immunohistochemistry comparability study in real-life
clinical samples: Results of Blueprint print phase 2 project. J
Thorac Oncol. 13:1302–1311. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li Z, Maeda D, Yoshida M, Umakoshi M,
Nanjo H, Shiraishi K, Saito M, Kohno T, Konno H, Saito H, et al:
The intratumoral distribution influences the prognostic impact of
CD68- and CD204-positive macrophages in non-small cell lung cancer.
Lung Cancer. 123:127–135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tanaka R, Ichimura Y, Kubota N, Saito A,
Nakamura Y, Ishitsuka Y, Watanabe R, Fujisawa Y, Mizuno S,
Takahashi S, et al: Differential involvement of programmed cell
death ligands in skin immune responses. J Invest Dermatol.
142:145–154.e8. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sanmamed MF and Chen L: Inducible
expression of B7-H1 (PD-L1) and its selective role in tumor site
immune modulation. Cancer J. 20:256–261. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y
and Zhang P: Interferon-γ-induced PD-L1 surface expression on human
oral squamous carcinoma via PKD2 signal pathway. Immunobiology.
217:385–393. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lane RS, Femel J, Breazeale AP, Loo CP,
Thibault G, Kaempf A, Mori M, Tsujikawa T, Chang YH and Lund AW:
IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells
in melanoma and inflamed skin. J Exp Med. 215:3057–3074. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qian J, Wang C, Wang B, Yang J, Wang Y,
Luo F, Xu J, Zhao C, Liu R and Chu Y: The IFN-γ/PD-L1 axis between
T cells and tumor microenvironment: Hints for glioma
anti-PD-1/PD-L1 therapy. J Neuroinflammation. 15:2902018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen S, Crabill GA, Pritchard TS, McMiller
TL, Wei P, Pardoll DM, Pan F and Topalian SL: Mechanisms regulating
PD-L1 expression on tumor and immune cells. J Immunother Cancer.
7:3052019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Arrieta O, Montes-Servin E,
Hernandez-Martinez J, Cardona AF, Cases-Ruiz E, Crispin JC, Motola
D, Flores-Estrada D and Barrera L: Expression of PD-1/PD-L1 and
PD-L2 in peripheral T-cells from non-small cell lung cancer
patients. Oncotarget. 8:101994–102005. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kitsou M, Ayiomamitis GD and Zaravinos A:
High expression of immune checkpoints is associated with the TIL
load, mutation rate and patient survival in colorectal cancer. Int
J Oncol. 57:237–248. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng
Q, Wei M, Zhang B and Yu X: A PD-L2-based immune marker signature
helps to predict survival in resected pancreatic ductal
adenocarcinoma. J Immunotherapy Cancer. 7:2332019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mei J, Xiao Z, Guo C, Pu Q, Ma L, Liu C,
Lin F, Liao H, You Z and Liu L: Prognostic impact of
tumor-associated macrophage infiltration in non-small cell lung
cancer: A systemic review and meta-analysis. Oncotarget.
7:34217–34228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jackute J, Zemaitis M, Pranys D,
Sitkauskiene B, Miliauskas S, Vaitkiene S and Sakalaukas R:
Distribution of M1 and M2 macrophages in tumor islets and stroma in
relation to prognosis of non-small cell lung cancer. BMC Immunol.
19:32018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mantovani A, Sozzani S, Locati M, Allavena
P and Sica A: Macrophage polarization: Tumor-associated macrophages
as a paradigm for polarized M2 mononuclear phagocytes. Trends
Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gabrusiewicz K, Li X, Wei J, Hashimoto Y,
Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, et al:
Glioblastoma stem cell-derived exosomes induce M2 macrophages and
PD-L1 expression on human monocytes. Oncoimmunology.
7:e14129092018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wen ZF, Liu H, Gao R, Zhou M, Ma J, Zhang
Y, Zhao J, Chen Y, Zhang T, Huang F, et al: Tumor cell-released
autophagosomes (TRAPs) promote immunosuppression through induction
of M2-like macrophages with increased expression of PD-L1. J
Immunother Cancer. 6:1512018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning
W, Zeng H, Zhang N, Du W, Chen C and Huang JA: PD-L1 induced by
IFN-γ from tumor-associated macrophages via the JAK/STAT3 and
PI3K/AKT signalling pathways promoted progression of lung cancer.
Int J Clin Oncol. 22:1026–1033. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tsukamoto M, Imai K, Ishimoto T, Komohara
Y, Yamashita Y, Nakagawa S, Umezaki N, Yamao T, Kitano Y, Miyata T,
et al: PD-L1 expression enhancement by infiltrating
macrophage-derived tumor necrosis factor-α leads to poor pancreatic
cancer prognosis. Cancer Sci. 110:310–320. 2019.PubMed/NCBI
|
|
42
|
Lai YS, Wahyuningtyas R, Aui SP and Chang
KT: Autocrine VEGF signalling on M2 macrophages regulates PD-L1
expression for immunomodulation of T cells. J Cell Mol Med.
23:1257–1267. 2019.PubMed/NCBI
|
|
43
|
Lin C, He H, Liu H, Li R, Chen Y, Qi Y,
Jiang Q, Chen L, Zhang P, Zhang H, et al: Tumor-associated
macrophage-derived CXCL8 determines immune evasion through
autonomous PD-L1 expression in gastric cancer. Gut. 68:1764–1773.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Horlad H, Ma C, Yano H, Pan C, Ohnishi K,
Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, et al: An
IL-27/Stat3 axis induces expression of programmed death ligands
(PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci.
107:1696–1704. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cai X, Yuan F, Zhu J, Yang J, Tang C, Cong
Z and Ma C: Glioma-associated stromal cells stimulate glioma
malignancy by regulating the tumor immune microenvironment. Front
Oncol. 11:6729282021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang J, Li D, Cang H and Guo B: Crosstalk
between cancer and immune cells: Role of tumor-associated
macrophages in the tumor microenvironment. Cancer Med. 8:4709–4721.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Menguy S, Prochazkova-Carlotti M,
Beylot-Barry M, Saltel F, Vergier B, Merlio J and Pham-Ledard A:
PD-L1 and PD-L2 are differentially expressed by macrophages or
tumor cells in primary cutaneous diffuse large B-cell lymphoma, Leg
type. Am J Surg Pathol. 42:326–334. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pinato DJ, Vallipuram A, Evans JS, Wong C,
Zhang H, Brown M, Dina RE, Trivedi P, Akarca AU, Marafioti T, et
al: Programmed cell death ligand expression drives immune
tolerogenesis across the diverse subtypes of neuroendocrine tumors.
Neuroendocrinology. 111:465–474. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y,
Zhang Q, Zhang F, Liu H, Li T, et al: The clinicopathological and
prognostic significance of PD-L1 expression assessed by
immunohistochemistry in lung cancer: A meta-analysis of 50 studies
with 11,383 patients. Transl Ling Cancer Res. 8:429–449. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yu W, Hua Y, Qiu H, Hao J, Zou Z, Li Z, Hu
S, Guo P, Chen M, Sui S, et al: PD-L1 promotes tumor growth and
progression by activating WIP and β-catenin signaling pathways and
predicts poor prognosis in lung cancer. Cell Death Dis. 11:5062020.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sato M, Shames DS and Hasegawa Y: Emerging
evidence of epithelial-to-mesenchymal transition in lung
carcinogenesis. Respirology. 17:1048–1059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Brabletz S, Schuhwerk H, Brabletz T and
Stemmler MP: Dynamic EMT: A multi-tool for tumor progression. EMBO
J. 40:e1086472021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Inoue Y, Yoshimura K, Nishimoto K, Inui N,
Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T,
et al: Evaluation of programmed death ligand 1 (PD-L1) gene
amplification and response to nivolumab monotherapy in non-small
cell lung cancer. JAMA Netw Open. 3:e20118182020. View Article : Google Scholar : PubMed/NCBI
|
